



Kimberly Bertrand, Sc.D., M.P.H., Boston University School of Medicine and Slone Epidemiology Center

Kimberly Bertrand, Sc.D., is Assistant Professor at the Boston University School of Medicine and Epidemiologist at the Slone Epidemiology Center at Boston University. Since 2015, she has been Co-Investigator on the Black Women's Health Study. Dr. Bertrand's current research efforts focus primarily on the epidemiology of breast cancer and hematological malignancies, with an emphasis on understanding racial disparities in risk and outcomes.




Paul Brennan, Ph.D., M.S., International Agency for Research on Cancer

Dr. Paul Brennan is an epidemiologist and the Head of the Genetics Section at the International Agency for Research on Cancer (IARC) in Lyon, France. He received his Ph.D. in Genetic Epidemiology from the University of Manchester, UK, and his M.S. in Medical Statistics from the University of Leicester, UK. His work is focused on identifying cancer predisposition genes through either genotyping or sequencing of very large numbers of cases and controls, and using biomarkers to help identify non-genetic risk factors for cancer, and even help identify early stage cancers. Dr. Brennan is involved in several NCI Cohort Consortium projects including the HPV Cancer Cohort Consortium, the Lung Cancer Cohort Consortium, and the Impact of Alcohol Use on Cancer Incidence and Mortality.



Peter Campbell, Ph.D., M.S., American Cancer Society

Dr. Campbell is a scientific director in the Department of Population Science at the American Cancer Society (ACS). He primarily leads the gastrointestinal tract cancer epidemiology research at ACS, using internal resources, such as the Cancer Prevention Studies (CPS) II and III and their respective biorepositories, and in various large, international groups' collaborations. Dr. Campbell is also an adjunct Professor in the Rollins School of Public Health and the Winship Cancer Institute, both at Emory University. The overarching goal of his research is to better understand why some lifestyle/behavioral factors influence cancer risk or prognosis with a view to better inform and support the primary prevention of cancer and the care of cancer patients. Dr. Campbell received his Ph.D. in Epidemiology from the University of Toronto and his M.S. from York University. He is involved in several different NCI Cohort Consortium projects including leading the Colorectal Cancer Pooling Project and co-leading the Biliary Tract Cancer Pooling Project, Liver Cancer Pooling Project, and Serologic Inflammatory Markers and Esophageal Adenocarcinoma Risk.



Sean Coady, M.A., National Heart, Lung, and Blood Institute

Mr. Coady is an acting deputy branch chief in the Epidemiology Branch, Division of Cardiovascular Sciences, at NHLBI. He has been with NHLBI for 22 years and has managed the data repository for nearly 20 years. In addition to managing the data repository, Mr. Coady maintains a grant portfolio composed primarily of training awards and R01 grants, and is the project scientist for the Risk Underlying Rural Areas Longitudinal (RURAL) Heart and Lung Study. He is also serving as the program lead in the Institute's Cohort of Cohorts for COVID-19 research initiative.



**Stephen J. Chanock, M.D., Director, National Cancer Institute,
Division of Cancer Epidemiology & Genetics**

Dr. Stephen Chanock is a leading expert in the discovery and characterization of cancer susceptibility regions in the human genome. He has received numerous awards for his scientific contributions to our understanding of common and rare inherited genetic variants associated with cancer risk and outcomes.

Dr. Chanock received his M.D. from Harvard Medical School and completed clinical training in pediatrics, pediatric infectious diseases, and pediatric hematology/oncology, and research training in molecular genetics at Boston Children's Hospital and the Dana-Farber Cancer Institute, Boston. For 25 years, Dr. Chanock served as the Medical Director for Camp Fantastic, a week-long recreational camp for pediatric cancer patients, which is a joint venture of the NCI and Special Love, Inc.

From 2001 to 2007, he was a tenured investigator in the Genomic Variation Section of the Pediatric Oncology Branch in the NCI Center for Cancer Research. He also served as co-chair of the NCI Genetics, Genomics and Proteomics Faculty for five years. In 2001, he was appointed as Chief of the Cancer Genomics Research Laboratory (formerly Core Genotyping Facility), and in 2007 as Chief of the Laboratory of Translational Genomics, both within the NCI Division of Cancer Epidemiology and Genetics (DCEG). Dr. Chanock co-led the Cancer Genetic Markers of Susceptibility project. From 2012 to 2013, he also served as Acting Co-Director of the NCI Center for Cancer Genomics. Dr. Chanock was appointed Director of DCEG in August 2013.



**Robert Croyle, Ph.D., Director, National Cancer Institute, Division of
Cancer Control and Population Sciences**

Robert Croyle, Ph.D., was appointed director of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI) in July 2003. In this role, he is responsible for overseeing a research portfolio and operating budget of over half a billion dollars and serves on NCI's Scientific Program Leaders governance group. As a division, DCCPS covers a wide range of scientific domains and disciplines, including epidemiology, behavioral science, surveillance, cancer survivorship, and health services research. He previously served as the division's associate director for the Behavioral Research Program, leading its development and expansion. Before coming to NCI in 1998, he was professor of psychology and a member of the Huntsman Cancer Institute at the University of Utah in Salt Lake City. Prior to that, he was a visiting

investigator at the Fred Hutchinson Cancer Research Center in Seattle, visiting assistant professor of psychology at the University of Washington, and assistant professor of psychology at Williams College in Massachusetts.

Dr. Croyle received his Ph.D. in social psychology from Princeton University in 1985, and graduated Phi Beta Kappa with a B.A. in psychology from the University of Washington in 1978. His research has examined how individuals process, evaluate, and respond to cancer risk information, including tests for inherited mutations in BRCA1 and BRCA2. His research has been published widely in professional journals in behavioral science, public health, and cancer, and he has edited two volumes: *Mental Representation in Health and Illness* (1991) and *Psychosocial Effects of Screening for Disease Prevention and Detection* (1995). He is co-editor of the *Handbook of Cancer Control and Behavioral Science* (2009) and co-author of *Making Data Talk: Communicating Public Health Data to the Public, Policy Makers and the Press* (2009). He is also co-editor of *Strategies for Team Science Success* (currently in press).

Dr. Croyle is a member of the Academy of Behavioral Medicine Research, a Fellow of the Society of Behavioral Medicine, a Fellow of the American Psychological Association, and a recipient of several awards for his research and professional service. His efforts on journal editorial boards include being associate editor for *Cancer Epidemiology, Biomarkers and Prevention*, and consulting editor for *Health Psychology* and the *British Journal of Health Psychology*. Dr. Croyle received the American Psychological Association Nathan Perry Career Service to Health Psychology Award in 2009, and an APA Presidential Citation for science and leadership in 2012. Dr. Croyle received the NIH Merit Award in 1999, 2002, and 2008. He received the NIH Director's Award in 2000 and 2015, and the NIH Office of the Director Honor Award in 2013. In 2014, he received the Distinguished Achievement Award from the American Society of Preventive Oncology.



Robert Eiss, M.A., National Institutes of Health

Robert Eiss is senior global health adviser to the Director of the National Institutes of Health and Fogarty International Center. At NIH, Mr. Eiss assumed lead responsibility for the Fogarty International Center's first long-range plan, which reoriented its programs to address infectious and non-communicable disease research and training needs of low- and middle-income countries. Mr. Eiss has held executive management posts at the White House Office of National Drug Control Policy (ONDCP) and at an international NGO established by the Rockefeller Foundation to improve access to innovative medicines. At ONDCP, he served as director of planning and

budget, involving budgetary oversight of national drug control agencies, establishment of a system of performance measures to monitor program effectiveness, and the management of a research portfolio on illicit drug consumption and consequences. As CEO of an international NGO, he promoted innovative and strategic management of intellectual property to speed the development of medical products that reduce global health disparities. Mr. Eiss holds degrees from the University of Maryland at College Park and Oxford University.



Renée Fortner, Ph.D., German Cancer Research Center

Dr. Renée Fortner leads the Hormones and Cancer Group in the Division of Cancer Epidemiology at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. The goal of Dr. Fortner's research is to provide meaningful, actionable knowledge on the etiology of breast and gynecologic cancers toward prevention and earlier detection. To that end, she conducts studies on lifestyle and reproductive factors, as well as circulating hormones, hormonally active metabolites, growth factors, inflammation factors, and markers of infection in relation to cancer risk, and is active in investigations of serologic markers for ovarian cancer early detection. Dr. Fortner earned her Ph.D. in epidemiology at the University of Massachusetts Amherst, and completed a postdoctoral fellowship at the Harvard School of Public Health before joining the DKFZ. She co-chairs the European Investigation into Cancer and Nutrition (EPIC) cohort gynecologic cancer working group.



Geoffrey S. Ginsburg, M.D., Ph.D., Duke University School of Medicine

Dr. Ginsburg is the founding director for the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center and for MEDx, a partnership between the Schools of Medicine and Engineering to spark and translate innovation. His research addresses the challenges for translating genomic and digital health information into medical practice, and the integration of precision medicine into healthcare. In 2017, he received Duke's Translational Research Mentorship Award and was a finalist in the NIH/BARDA Antimicrobial Resistance Prize.

He was a member of the Advisory Council to the Director of NIH, is the co-chair of the National Academies Roundtable on Genomic and Precision Health, and is the founder and president of the Global Genomic Medicine Collaborative, a not-for-profit (501c(3)) dedicated to implementing genomic medicine with a focus on low resource settings around the globe. The G2MC operates the International 100K+ Cohorts Consortium, of which he is one of the co-chairs, along with Teri Manolio (NHGRI) and Peter Goodhand (GA4GH).

He has recently served as a member of the Board of External Experts for the NHLBI, the advisory council for the National Center for Accelerating Translational Science, chair of the review for Genome Canada's Large Scale Applied Research Competition in Genomics and Precision Medicine, and the World Economic Forum's Global Agenda Council on the Future of the Health Sector. He is a founder of Predigen, Inc. and MeTree&You, Inc. He was previously Vice President of Molecular Medicine at Millennium Pharmaceuticals, Inc. and a faculty member at Harvard Medical School.



Holly Harris, Sc.D., M.P.H., Fred Hutchinson Cancer Research Center

Dr. Holly Harris is a public health researcher who studies the impact of lifestyle, nutrition, and genetic factors on women's health. She focuses specifically on ovarian and breast cancer, as well as the hormonally related conditions that share reproductive risk factors with these diseases such as endometriosis and uterine fibroids. Much of Harris' research focuses on the potentially modifiable factors of diet and lifestyle on the risk of these conditions; she also explores their interrelatedness and shared risk factors. For instance, women with endometriosis may be at higher risk for ovarian cancer and, thus, may benefit from screening modalities not appropriate for the population at large. Identification of women at high risk for ovarian and breast cancer allows for targeted prevention strategies and can guide clinical decisions regarding frequency of screening and chemoprevention strategies. Dr. Harris believes that understanding the influence of genetic factors, both alone and as a part of gene-environment interactions, may facilitate prevention and help identify women most at risk for ovarian and breast cancer. She also led a study that found a link between childhood abuse and endometriosis; women who reported severe to chronic abuse had a 79 percent higher risk of developing the condition. Dr. Harris received her Sc.D. degree in Epidemiology from Harvard T.H. Chan School of Public Health and her M.P.H. degree in Epidemiology/Biostatistics from the University of Southern California.



Justin Hentges, M.P.P., All of Us Research Program, National Institutes of Health

Justin Hentges, M.P.P., is the Chief Financial and Management Officer for the *All of Us* Research Program. Prior to joining *All of Us*, Justin served as the senior advisor for accountability and oversight to the Assistant Secretary for Financial Resources (ASFR) at the Department of Health and Human Services. During his almost 4 years in this role, Justin was an integral part of the Department's response to Congress, the Government Accountability Office, and oversight from the Office of Inspector General; the implementation of major pieces of legislation, including the Federal Information Technology Acquisition Reform Act; and the planning for the 2017 presidential administration transition. Justin also served as an active member of the HHS LGBT Policy Coordinating Committee. Justin began his federal career at the NIH in the Administrative Fellows Program, a 2-year administrative leadership training program. During his federal career, he also served as a budget analyst for the National Institute of Dental and Craniofacial Research, as a program analyst in the ASFR Office of Budget, and as the Special Assistant to the NIH Deputy Director. While Special Assistant, Justin was the lead staff for the Advisory Committee to the Director Working Group on Diversity in the Biomedical Research Workforce. Justin has a Bachelor of Arts in political science and economics from the University of Wisconsin-Eau Claire and a Master of Public Policy from George Mason University. Justin lives in D.C. with his partner, Matt, and their cat, Mo, and dog, Luna.



Jill Koshiol, Ph.D., National Cancer Institute, Division of Cancer Epidemiology & Genetics

Dr. Jill Koshiol received her Ph.D. in epidemiology from the University of North Carolina at Chapel Hill School of Public Health in 2005 and subsequently joined the National Cancer Institute. She is currently a tenure-track investigator in the Infections and Immunoepidemiology Branch of the Division of Cancer Epidemiology and Prevention. She studies the natural history of hepatobiliary cancers and the role of inflammation in these cancers to better understand how they develop and to identify new opportunities for cancer prevention and early detection.

James V. Lacey, Jr., Ph.D., M.P.H., City of Hope



Dr. Lacey is a Professor and Director of the Division of Health Analytics within the Department of Computational and Quantitative Medicine at City of Hope. He and Dr. Elena Martinez are the Multiple Principal Investigators for the California Teachers Study (CTS) cohort.

Lacey's work increasingly involves improving cohort infrastructure through epidemiology-driven use of informatics, data science, and data analytics. Since 2013, he has led the CTS as it replaced its previous data infrastructure with a combination of a CRM platform, integrated mobile devices for data collection, and an analytic environment that is consistent with the NCI's Data Commons Framework. Before joining City of Hope and the CTS in 2009, he spent 11 years with the NCI's Division of Cancer Epidemiology and Genetics. His research there helped to understand the natural history of uterine cancer and to uncover links between menopausal hormone therapy and risks of uterine and ovarian cancers. Dr. Lacey received his Ph.D. and M.P.H. from the University of Michigan School of Public Health in Ann Arbor. Since 2015, he has served as a member of the NCI's Board of Scientific Advisors.

Susan Pinney, Ph.D., M.S., University of Cincinnati College of Medicine




Susan M. Pinney, Ph.D., FACE, is a Professor in the Department of Environmental Health in the College of Medicine, University of Cincinnati; the Director of the Center for Environmental Genetics; and the Cancer Risk, Control and Prevention Program Leader for the Cincinnati Cancer Center. She conducts a variety of large molecular epidemiology studies, with research focused on the environmental factors that influence the age at pubertal events such as breast development (and risk of breast cancer later in life).

She also conducts cohort studies of the gene variants that result in great risk of lung cancer and the health effects of uranium exposure. Since 1990, she has been the Research Director of the Fernald Community Cohort, with data and biospecimens collected over 18 years, which have been used for over 85 research studies. Dr. Pinney received her Ph.D. in Epidemiology from the University of Cincinnati and her M.S. from the University of Michigan, Ann Arbor.



Hilary Robbins, Ph.D., M.H.S., M.S.P.H., International Agency for Research on Cancer

Dr. Hilary Robbins is an epidemiologist at the International Agency for Research on Cancer (IARC) in Lyon, France. She trained at Johns Hopkins Bloomberg School of Public Health (Ph.D., M.H.S., M.S.P.H.) and the U.S. National Cancer Institute (fellowship). Her work is focused on risk-tailored approaches to cancer screening, using tools such as risk prediction models and biomarkers. Current projects include validating lung cancer risk prediction models for different countries and ethnicities, developing a protein biomarker panel for applications in lung cancer screening, and investigating early detection biomarkers for HPV-related oropharyngeal cancer. Dr. Robbins co-leads the Lung Cancer Cohort Consortium, and is also involved in leadership of the HPV Cancer Cohort Consortium.



Emma Spielfogel, B.A., City of Hope

Emma Spielfogel is a Data Analyst for the California Teachers Study. She first became involved with the CTS as an intern directly after completing her Bachelor of Arts with double majors in Biology and French Studies at Occidental College. She spent a year teaching English at a high school in France and then joined the CTS full-time in October 2018.

Emma provides technical and analytic support to everyone who conducts research on CTS data. She maintains and manages documentation and user-facing materials in the CTS shared workspace. Emma also leads the CTS's data visualization work, both for individual projects and the interactive features on the CTS website. Emma's work focuses on process improvement and the development of innovative materials that enable user-friendly navigation of CTS data.



Britton Trabert, Ph.D., M.S.P.H., National Cancer Institute, Division of Cancer Epidemiology & Genetics

Dr. Britton Trabert is an Earl Stadtman Tenure-Track Investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute. Dr. Trabert's research program focuses on clarifying the role of systemic and local (tubal) inflammation and infection in gynecologic cancer. She has published and continues to lead studies in OC3 to understand the role of anti-inflammatory medications, particularly low-dose aspirin, in reducing ovarian cancer risk. In addition to her work focused on the inflammatory origins of ovarian cancer, Dr. Trabert also leads research focused on the hormonal etiology of female cancers. Dr. Trabert earned her M.S.P.H. in epidemiology from Emory University, her M.S. in biostatistics from the University of Michigan, and her Ph.D. in epidemiology from the University of Washington with a focus in reproductive epidemiology and women's health before completing postdoctoral training at the National Cancer Institute.



Giske Ursin, M.D., Ph.D., Cancer Registry of Norway

Dr. Giske Ursin is Director of the Cancer Registry of Norway. She is Professor II at the Institute of Basic Medical Sciences at the University of Oslo, and Professor Emerita at the Department of Preventive Medicine, Keck School of Medicine at the University of Southern California. The Cancer Registry of Norway is a research institution that runs the cancer registry, the clinical registries on cancer, as well as the national cancer screening programs. Dr. Ursin is a cancer epidemiologist involved in large epidemiological studies and registry linkages in Norway, and with close collaborations with the other Nordic cancer registries.